News

Shilpa Biologicals and IIT Dharwad Sign Strategic MoU to Strengthen Industry-Academia Collaboration
Jan 21, 2026

Shilpa Biologicals, Dharwad, has entered into a strategic Memorandum of Understanding (MoU) with the Indian Institute of Technology Dharwad (IIT Dharwad) on 21 January 2026, aimed at fostering a long-term collaborative framework between industry and academia.
The partnership brings together Shilpa Biologicals’ industrial expertise and IIT Dharwad’s research capabilities in biosciences, biotechnology, chemical engineering, and allied disciplines. It is designed to promote joint research and development, facilitate technology translation, support innovation-driven solutions, and address real-world industrial challenges.
Under the collaboration, both organizations will work closely on joint research projects, student internships, faculty-industry interactions, skill development programs, and supervision of research scholars. The MoU also seeks to advance innovation in biopharmaceutical processes, sustainable biomanufacturing, and advanced biotechnological solutions — contributing to national priorities in healthcare and technology-led growth.
This partnership is expected to create meaningful opportunities for students, researchers, and industry professionals, while reinforcing the commitment of Shilpa Biologicals to academic engagement and innovation excellence.

Know More
Dear Our Trade Distributors, Stockiest & Business Associates
Sep 22, 2025

We wish to inform you that, in accordance with the latest directives from the GST Council and the National Pharmaceutical Pricing Authority (NPPA), significant changes to the Goods and Services Tax (GST) and Drugs (Prices Control) Order (DPCO) will come into effect starting 22nd September 2025. In line of these guideline , Shilpa Medicare Ltd is publishing the Product Information like Brand Name, generic Name, PTS, PTR ,Old MRP , Old GST Rate & Revised GST Rate along with Revised MRP effective from 22nd Sep 2025 to ease the Business Operation of Our All Associates along with Awareness on Pricing & tax Structure . It is mandatory to pass the Benefit of Reduction of GST rate to ultimate customer. Attached is the Guideline & Product Details .

Know More
Shilpa Medicare Ltd has launched Sunitinib Capsules 12.5 mg, 25 mg & 50 mg in Indian market under brand name "SUNISHIL".
Sep 21, 2025

Shilpa Medicare Ltd has launched Sunitinib Capsules 12.5 mg, 25 mg & 50 mg in Indian market under brand name "SUNISHIL". Sunitinib Capsules are indicated for the treatment of Gastrointestinal stromal tumour (GIST), Metastatic renal cell carcinoma (MRCC) & Pancreatic neuroendocrine tumours (pNET). SUNISHIL is a therapeutic equivalent of the brand leader SUTENT.

Shilpa Medicare arm partners with Orion Corporation for Recombinant Human Albumin for European Market
May 23, 2025

In Conversation: Dr. Sridevi on PharmTech’s Latest Podcast
May 8, 2025
Know More View PDF
Shilpa Biologicals opens bioconjugation manufacturing site for fully integrated ADC development
May 5, 2025
New bioconjugation services to complete the CDMO’s end-to-end capabilities across payload, linker, and MAb
Know More
Media Spotlight: Our New ADC Bioconjugation Facility

Shilpa Biologicals Pvt Ltd signs strategic development partnership with mAbTree Biologics AG for a novel immuno-oncology asset
March 17, 2025
Shilpa to undertake both development and commercial supply for mAbTree’s novel checkpoint inhibitor
Know More
Shilpa Launches ‘hybrid CDMO’ at DCAT
March 10, 2025
Integrated CDMO has capabilities spanning small and large molecules as well as peptides with ‘off-the-shelf’ commercially ready formulations for license
Know More
Shilpa Biologicals’ CDMO Journey Spotlighted in This Month’s BioProcess Insider
View PDF
Shilpa Medicare arm appoints Dr. Sridevi Khambhampaty as CEO
September 19, 2024
Know More
Shilpa Medicare Limited (SML) has received the Marketing Authorization Permission for its Adalimumab
June 27, 2023
We are delighted to announce that Shilpa Biologicals Private Limited (SBPL), a wholly owned subsidiary of Shilpa Medicare Limited (SML), has received the Marketing Authorization Permission for its Adalimumab 40 mg/0.4mL injection in prefilled syringe (PFS), a biosimilar of Adalimumab higher concentration formulation (100mg/mL) in India. This is used for the treatment of Rheumatoid Arthritis (moderate to severe active RA & severe active and progressive RA) for which the phase 3 clinical trial has been successfully completed in Q3 2022. This formulation will contribute to increased patient comfort based on reduced injection volume.

Shilpa Biologicals' extensive research and development efforts have resulted in the successful development of a high concentration biosimilar that matches the safety, purity, and potency profiles of the reference product. This achievement underscores the company's commitment to development of biosimilars and its mission to improve global healthcare outcomes. SBPL has been working on development of biosimilars catering to different therapeutic areas such as Immunology, Oncology, Ophthalmology, among which, Adalimumab is the first Biosimilar from Shilpa Biologicals Private Limited.
Know More
Shilpa Biologicals completes Human Clinical Studies of its Adalimumab biosimilar
August 19, 2022
Know More
Shilpa Medicare arm gets NoC to conduct clinical studies for its Biosimilar Aflibercept
April 25, 2022
Know More
Mylab partners with Shilpa Biologicals to enter vaccines & therapeutics segment
February 11, 2022
Know More
Shilpa Medicare to make drug substance for Cadila’s ZyCoV-D vaccine
September 25, 2021
Know More
Shilpa Medicare ties up with Dr Reddy’s for production of Sputnik V vaccine
May 17, 2021
Know More